DailyIQ
Last updated1 minute ago

HUM·Humana Inc.

$404.27
+0.20 (+0.05%)
Overnight$404.27+0.00 (+0.00%)
High
$408.04
Open
$405.02
Market Cap
46.71B
52W High
$434.95
Low
$396.04
P. Close
$404.27
P/E
36.52
52W Low
$163.11
Fwd P/E
24.36
DailyIQ Est.
$433.65
Inst. Ownership
49.7%
Short Interest
2.46%
Days to Cover
3.3
Technical Score (1D)
82
BULLISH
News Sentiment
42
BEARISH
On Oct 5, UnitedHealth Group announced it would discontinue about 390,000 Medicare Advantage members in 2027 as rising medical costs eroded profitability. The company’s selective exit targeted high‑cost PPO‑based plans, aiming to improve the economics of its Medicare portfolio. The move was part of a broader industry shift toward plan‑level profitability and was expected to tighten margins for the insurer. UnitedHealth also planned to invest $1.5 billion in AI initiatives to offset administrative costs, but the plan exit underscored ongoing cost pressures. The announcement highlighted the company’s strategy to address margin erosion in its Medicare business.
LOW TARGET
$280 -30.7%
2 analysts
MEAN TARGET
$424 +4.8%
21 analysts
HIGH TARGET
$515 +27.4%
11 analysts
PRICE RANGE
$280.00 - $515.00
SB / B / H / S / SS
8/8/16/1/1
DAILYIQ EST.
$433.65 (+7.3%)
Sector
Healthcare
Industry
Healthcare Plans
Exchange
NYQ
Country
United States
Website
Symbol
HUM
Description
Humana Inc. is a U.S.-based healthcare company primarily focused on providing medical and specialty insurance products. Its core business revolves around two key segments: Insurance and CenterWell. Humana offers a range of health plans, including medical care, supplemental benefits, and prescription drug coverage, catering to individuals, employer groups, and government programs like Medicare and Medicaid. The company's value proposition extends to administrative services and specialized offerings such as dental, vision, and military healthcare through the TRICARE program. Humana differentiates itself through integrated services, including pharmacy benefit management, primary care centers, and home health solutions, providing a comprehensive approach to healthcare delivery for its members.
Bought (1Y)
0 shares
$0
Sold (1Y)
0 shares
$0
HILZINGER KURT J-
Award/Grant238 shares2026-09-30
Nundy ShantanuChief Medical Officer
Award/Grant2,549 shares2026-09-01
Crawford Frederick John-
Award/Grant544 shares2026-08-01
Smith Paul John-
Award/Grant544 shares2026-08-01
HILZINGER KURT J-
Award/Grant233 shares2026-06-30
83/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Net Margin
20.4%
Revenue CAGR
-7.8%
Current Ratio
2.00x
Debt / Equity
0.70x
Return on Equity
6.7%
Earnings Summary
Humana Inc. is a U.S.-based healthcare company that primarily offers medical and specialty insurance products through its Insurance and CenterWell segments, serving individuals, employer groups, and government programs such as Medicare and Medicaid, and differentiating itself with integrated services including pharmacy benefit management and home health solutions. In the most recent quarter, Q1 2026, Humana reported revenue of $39.65 billion, up from $32.61 billion in Q1 2025, reflecting a 21.5% year‑over‑year increase, while EPS rose to $10.31 from $11.58 in Q1 2025, a modest decline in earnings per share but still above the $10.15 estimate, indicating a continued ability to beat analyst expectations in the latest period. Historically, the company has shown a steady upward trajectory in revenue, with Q3 2025 revenue at $32.65 billion and Q4 2025 at $32.64 billion, while EPS has fluctuated, notably turning negative in Q4 2025 at –$3.96 versus a positive $10.57 estimate, yet the company has consistently beat estimates in 3 of the last 4 quarters, underscoring a pattern of revenue growth even when earnings miss. Recent news highlights Barclays’ upgrade to Overweight on September 25, driven by confidence in Humana’s Medicare Star ratings and potential bonus status under the H5216 contract, which lifted the stock and signaled a stronger outlook for Medicare earnings; additionally, the company’s pharmacy‑care coordination program has been shown to reduce hospitalizations for cancer patients, supporting cost‑efficiency and margin stability.

EPS

EstBeatMiss
$-6.14$-1.42$3.30$8.03$12.75Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$-1.00 - -
Q2'26$7.29$7.61+4.3%
Q1'26$10.16$10.31+1.5%
Q4'25$10.57$-3.96-137.5%
Q3'25$2.83$3.24+14.6%
Q2'25$5.87$6.27+6.9%

Revenue

EstBeatMiss
$31.1B$33.9B$36.8B$39.7B$42.6BQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$41.3B - -
Q2'26$41.0B$40.9B-0.3%
Q1'26$39.4B$39.6B+0.7%
Q4'25$35.5B$32.6B-8.1%
Q3'25 - $32.6B -
Q2'25 - $32.4B -

Market Data

HUM Stock Snapshot

BULLISH82/100
$404.27+$0.00 (0.0%)
Market cap
46.71B
P/E ratio
36.5
Day range
$396.04 – $408.04
News sentiment
42/100 · Neutral
Analyst target
$423.74 (+4.8%)
Consensus
Hold · 34 analysts
52-week range+147.9% off low · -7.1% from high
$163.11$434.95
Price $404.27 DailyIQ Est. $433.65

Humana Inc. screens well technically, with price sitting near its 52-week high. Institutional coverage is thorough here, so shifts in analyst expectations show up in price quickly.

Reverse DCF

What growth is priced into HUM?

RICH

At today's price, Humana Inc. needs to grow free cash flow about 56.2% a year for the next 10 years to justify its valuation at a 7.86% cost of capital. Over its actual history it has compounded free cash flow at 3.3% a year, so the market is asking for 52.9 percentage points above its own delivered rate. On that basis HUM looks priced above what its own growth record supports.

Implied FCF growth
56.2%
Historical FCF CAGR
3.3%
Growth gap
+52.9 pts
Verdict
RICH
Discount rate (WACC)
7.86%
Beta
0.71

Behaviour On Record

What HUM's own history says about today's numbers

Realized volatility (21d)
31.7% 68th pct
Below its peak
-28.4%
vs 200-day average
+37.6%
Up days (1y)
53%

Humana Inc. is currently running 31.7% annualised volatility over the last 21 sessions. Measured against HUM's own 13 years of daily returns rather than a market-wide average, that is the 68th percentile — a little above its own norm, against a typical reading of 25.2%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

HUM is trading -28.4% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -22.5%, and the deepest was -49.9% in 2024. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.

Price sits +37.6% from its 200-day moving average. Against every other day in its history, that gap ranks at the 97th percentile — a wider gap than this stock usually carries. Over the past year HUM closed higher on 53% of sessions, and it is currently 2 sessions into a rising streak.

On October specifically: over 13 years of records, HUM finished the month higher 7 of 13 times, with a median return of +4.2% and an average of +4.3%. Its strongest month historically has been May at +6.5% on average, its weakest January at -3.8%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: HUM has opened more than 2% away from the prior close in 101 of 3,268 sessions (3.1% of the time), with the largest gaps running +8.9% and -11.8%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, HUM moved an average of 1.8% in the session after earnings, closing higher 2 of those 3 times, with a median move of +1.8% and a largest of -1.8%.

All figures computed from 3,269 daily closes between 2013-10-07 and 2026-10-05, split-adjusted, recomputed daily. Percentiles are against HUM's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of HUM's sector?

Humana Inc. sits in the Health Care sector, currently ranked 8th of 12 GICS sectors by relative-strength rotation score (lagging).

Sector rank
#8 of 12
Sector state
Lagging
Sector rotation score
0

Options Market

What is the options market pricing for HUM?

CallsPuts

For Humana Inc.'s nearest expiry (2026-10-09, 2 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.65), with at-the-money implied volatility around 156.4%. The options market is pricing roughly a ±11.4% move by that expiry — a range of about $340.12–$427.56.

Put/call ratio (2026-10-09)
0.65
ATM implied volatility
156.4%
Total open interest
12,098
Expected move by 2026-10-09
±11.4% ($340.12–$427.56)

Analyst Rating Changes

Are analysts turning bullish or bearish on HUM?

Barclays most recently upgraded Humana Inc. to Overweight on Sep 25, 2026 with a price target of $515 (from $407). Over the last 90 days, coverage has run 4 upgrades against 1 downgrade, a net bullish lean.

Latest action
Barclays — Overweight
90-day upgrades
4
90-day downgrades
1
Net rating momentum
+3
DateFirmActionRatingPrice target
Sep 25, 2026BarclaysUpgradeEqual-Weight → Overweight$407 → $515
Aug 10, 2026JP MorganMaintainedNeutral$316 → $393
Aug 5, 2026Morgan StanleyUpgradeUnderweight → Equal-Weight$249 → $370
Jul 31, 2026TD CowenMaintainedHold$350 → $370
Jul 31, 2026BarclaysMaintainedEqual-Weight$344 → $407
Jul 30, 2026UBSMaintainedNeutral$320 → $405
Jul 30, 2026Evercore ISI GroupUpgradeIn-Line → Outperform$430 → $480
Jul 30, 2026GuggenheimMaintainedBuy$269 → $471
Jul 30, 2026Raymond JamesDowngradeOutperform → Market Perform-
Jul 14, 2026TD CowenMaintainedHold$211 → $350
Jul 14, 2026Truist SecuritiesMaintainedHold$320 → $415
Jul 13, 2026Wells FargoUpgradeEqual-Weight → Overweight$227 → $502

HUM Competitive Positioning

Humana Inc. (HUM) is tracked alongside these names in Healthcare Plans on DailyIQ — ranked by market cap, with today's move alongside.

News Sentiment Analysis

Sentiment gathered from recent headlines

42/100
Strong NegativeNeutralStrong Positive
BEARISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
UnitedHealth Group announced it would discontinue about 390,000 Medicare Advantage members in 2027 as rising medical costs erode profitability. The company’s selective exit targets high‑cost PPO‑based plans, aiming to improve the economics of its Medicare portfolio. The move is part of a broader industry shift toward plan‑level profitability and is expected to tighten margins for the insurer. UnitedHealth also plans to invest $1.5 billion in AI initiatives to offset administrative costs, but the plan exit underscores ongoing cost pressures.
What did this article say?
Humana (HUM) disclosed that approximately 600,000 Medicare Advantage members—about 8% of its base—will lose their plans in 2027, coinciding with higher out‑of‑pocket costs and Part D deductibles. The company noted that members whose plans are discontinued will have a guaranteed issue right to purchase Medigap without medical underwriting, a benefit that may not reopen for those with chronic conditions. The announcement was made during the third‑quarter earnings release, highlighting membership and cost pressures that could affect future margins.
What did this article say?
Humana announced on Oct 1 that it would keep its Medicare Advantage plans affordable and broaden specialized care offerings for 2027. The company outlined new care pathways and service enhancements aimed at improving member experience. The move is intended to strengthen Humana's competitive position in the Medicare market. No immediate financial impact was disclosed.
What did this article say?
Humana announced that its 2027 Medicare Advantage plans will be available in roughly 2,600 counties across 45 states and Washington, D.C., covering more than 80% of U.S. counties. The plans will continue to offer $0 cost‑sharing for in‑network primary care visits and labs, and will include dental, vision, and hearing benefits. The company also expanded its Chronic Condition Special Needs coverage to better serve patients with multiple health conditions. These updates aim to enhance value for Medicare beneficiaries while maintaining Humana’s competitive positioning in the Medicare market.
What did this article say?
Humana’s stock rallied 136% over the past six months, driven by solid quarterly earnings and a robust Medicare Advantage portfolio. Analysts highlighted the company’s 12.8% annualized revenue growth and its heavy reliance on federal contracts as key growth drivers. The surge has prompted discussions about whether the market has overvalued the stock or if further upside remains. Investors are weighing the company’s long‑term momentum against potential valuation concerns. The commentary suggests a positive outlook but cautions that the gains may already be priced in.
What did this article say?
Barclays upgraded Humana (HUM) to Overweight from Equalweight, prompting a sharp rise in the stock. The rating change was interpreted as a signal that Humana could outperform sector peers, leading to a 4.63% one‑day gain and a 3.21% 30‑day return. The move reflects renewed investor confidence, though the company’s three‑year total shareholder return has fallen 15.34%, indicating the upgrade is seen as a fresh sentiment shift rather than a continuation of past performance.
What did this article say?
Barclays upgraded Humana (HUM) from Equalweight to Overweight, prompting an 8% jump in the stock price during the afternoon session. The rating change signals a more favorable outlook for the insurer, suggesting that analysts now expect better-than-average performance relative to its peers. The move reflects market confidence in Humana’s prospects but does not indicate a fundamental shift in the company’s business fundamentals.
What did this article say?
Barclays upgraded Humana to overweight from equal weight, raising its price target to $515 from $407. The upgrade was driven by expectations of improved Medicare Star ratings and the potential for several contracts to achieve bonus status. The move was reflected in a 5% rise in Humana shares on the day of the announcement. The upgrade signals a positive outlook for the insurer’s Medicare business and earnings trajectory.
What did this article say?
Barclays upgraded Humana (HUM) to overweight, raising its price target from $407 to $515. The announcement lifted the stock 5.7% on Friday, with trading volume exceeding 1.3 million shares, above the daily average. The upgrade signals stronger confidence in Humana’s earnings outlook and growth prospects, potentially influencing investor sentiment and valuation.

Technical Analysis

Real-time indicators across multiple timeframes

82
BULLISH
Technical indicators reflect the latest computed signal mix for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $19.79B combined position · 12 adding, 11 trimming, 2 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
BlackRock, Inc.▲ Buy10,417,8039.02%$4.14B2026-08-07
Vanguard Group Inc▲ Buy14,261,86012.34%$3.65B2026-01-29
JPMorgan Chase & Co▼ Sell4,087,8373.54%$1.59B2026-08-12
Geode Capital Management, LLC▲ Buy3,369,7572.92%$1.34B2026-08-12
Goldman Sachs Group Inc▲ Buy3,144,2892.72%$1.25B2026-08-14
FMR LLC (Fidelity)▲ Buy2,913,7632.52%$1.16B2026-08-13
Susquehanna International Group, LLP▼ Sell2,250,7701.95%$894.05M2026-08-14
Citadel Advisors LLC• Hold2,146,5221.86%$852.64M2026-09-02
Norges Bank▼ Sell1,748,4141.51%$694.51M2026-08-12
Invesco Ltd.▼ Sell1,478,7881.28%$587.40M2026-08-14
Morgan Stanley▼ Sell1,349,0661.17%$535.88M2026-08-13
Capital Research Global Investors▲ Buy1,116,9900.97%$443.46M2026-08-12
Northern Trust Corp▼ Sell1,115,1980.97%$442.98M2026-08-13
Capital World Investors▲ Buy1,022,4250.88%$406.12M2026-08-12
Wellington Management Group LLP▲ Buy765,3550.66%$304.01M2026-08-14
Bank of America Corp▼ Sell703,6150.61%$279.49M2026-08-14
Marshall Wace, LLP▲ Buy550,1780.48%$218.54M2026-08-13
Millennium Management LLC▲ Buy467,3980.40%$185.66M2026-08-14
Artisan Partners Limited Partnership▼ Sell684,7780.59%$175.39M2026-02-17
D. E. Shaw & Co., Inc.▼ Sell358,8430.31%$142.54M2026-08-14
Squarepoint Ops LLC▼ Sell274,4990.24%$109.04M2026-08-14
Neuberger Berman Group LLC▲ Buy267,3690.23%$106.20M2026-08-13
Glenview Capital Management, LLC▼ Sell254,2160.22%$100.98M2026-08-14
Davis Selected Advisers• Hold385,5390.33%$100.31M2025-12-29
Gotham Asset Management, LLC▲ Buy224,8600.19%$89.32M2026-08-14
Q2 2026 flow:2.42M sh bought ($962.77M)1.98M sh sold ($784.57M)net +447.9K sh (+$178.21M)
Congressional Trading Activity
15 disclosed trades · ~$120.0K est. traded value · 8 buys, 7 sells
MemberChamberStateTypeAmountTradedFiled
Alan ArmstrongSenateOK▲ Buy$1K - $15K2026-03-272026-07-21
Julia LetlowHouseLA05▼ Sell$1K - $15K2026-02-102026-03-12
Gilbert CisnerosHouseCA31▼ Sell$1K - $15K2025-11-122025-12-15
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-10-312025-11-21
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-10-302025-11-21
Lisa McClainHouseMI09▲ Buy$1K - $15K2025-10-302025-11-21
Lisa McClainHouseMI09▲ Buy$1K - $15K2025-09-252025-10-22
Julia LetlowHouseLA05▲ Buy$1K - $15K2025-08-082026-01-13
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2025-08-052025-09-12
Lisa McClainHouseMI09▲ Buy$1K - $15K2025-06-242025-08-13
Gilbert CisnerosHouseCA31▼ Sell$1K - $15K2025-05-302025-06-06
Rob BresnahanHousePA08▼ Sell$1K - $15K2025-05-152025-06-09
Gilbert CisnerosHouseCA31▼ Sell$1K - $15K2025-04-292025-05-06
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2025-02-262025-03-06
Rob BresnahanHousePA08▲ Buy$1K - $15K2025-02-252025-03-27